Cartesian Therapeutics announced participation in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026.
Quiver AI Summary
Cartesian Therapeutics, a biotechnology company focused on cell therapy for autoimmune diseases, announced that its management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 3:00 p.m. ET. The event will be available as a live webcast on the company's website, with an archived replay accessible for a limited time. Cartesian Therapeutics' lead asset, Descartes-08, is undergoing clinical trials for various autoimmune conditions, including Phase 3 development for generalized myasthenia gravis and Phase 2 trials for dermatomyositis and antisynthetase syndrome, among others. For more information, the company directs inquiries to their website and investor relations contacts.
Potential Positives
- Participation in a prominent investor conference showcases Cartesian Therapeutics' commitment to transparency and engagement with the investment community.
- The announcement of a live webcast allows for broader access to the company's updates, which can enhance investor interest and confidence.
- Highlighting the late-stage clinical development of their lead asset, Descartes-08, positions the company as a significant player in the biotech sector focused on autoimmune diseases.
Potential Negatives
- Management's announcement of participation in the investor conference may indicate a need to reassure investors amid uncertainty about the progress of their clinical developments.
FAQ
When is Cartesian Therapeutics participating in the BioConnect Investor Conference?
Cartesian Therapeutics will participate in the conference on May 19, 2026, at 3:00 p.m. ET.
Where can I watch the live webcast of the presentation?
The live webcast can be accessed in the Events section of the Company's website at www.cartesiantherapeutics.com.
What is the focus of Cartesian Therapeutics' research?
Cartesian Therapeutics focuses on pioneering cell therapy for autoimmune diseases.
What is Cartesian's lead asset in development?
The Company’s lead asset is Descartes-08, a CAR-T therapy currently in clinical development.
What autoimmune diseases are targeted by Cartesian's clinical trials?
The trials target generalized myasthenia gravis, myositis, and pediatric autoimmune diseases, among others.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RNAC Insider Trading Activity
$RNAC insiders have traded $RNAC stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $RNAC stock by insiders over the last 6 months:
- TIMOTHY C BARABE purchased 30,000 shares for an estimated $205,797
- CARSTEN BRUNN (President and CEO) sold 23,766 shares for an estimated $162,076
- BLAINE DAVIS (Chief Financial Officer) sold 10,591 shares for an estimated $72,227
- MILOS MILJKOVIC (Chief Medical Officer) sold 3,573 shares for an estimated $24,366
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RNAC Hedge Fund Activity
We have seen 45 institutional investors add shares of $RNAC stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 788,794 shares (-36.6%) from their portfolio in Q4 2025, for an estimated $5,687,204
- SIREN, L.L.C. removed 563,272 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,061,191
- MPM BIOIMPACT LLC removed 380,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,739,800
- MILLENNIUM MANAGEMENT LLC added 139,009 shares (+548.2%) to their portfolio in Q4 2025, for an estimated $1,002,254
- BANK OF AMERICA CORP /DE/ added 99,023 shares (+703.8%) to their portfolio in Q4 2025, for an estimated $713,955
- MARSHALL WACE, LLP added 93,334 shares (+110.1%) to their portfolio in Q4 2025, for an estimated $672,938
- TWO SIGMA INVESTMENTS, LP added 91,278 shares (+inf%) to their portfolio in Q4 2025, for an estimated $658,114
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RNAC Analyst Ratings
Wall Street analysts have issued reports on $RNAC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/19/2025
- BTIG issued a "Buy" rating on 11/14/2025
To track analyst ratings and price targets for $RNAC, check out Quiver Quantitative's $RNAC forecast page.
$RNAC Price Targets
Multiple analysts have issued price targets for $RNAC recently. We have seen 5 analysts offer price targets for $RNAC in the last 6 months, with a median target of $38.0.
Here are some recent targets:
- Martin Fan from Wedbush set a target price of $38.0 on 05/01/2026
- Kristen Kluska from Cantor Fitzgerald set a target price of $16.0 on 03/09/2026
- Gil Blum from Needham set a target price of $42.0 on 03/09/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $30.0 on 11/19/2025
- Julian Harrison from BTIG set a target price of $44.0 on 11/14/2025
Full Release
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4 th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET.
A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X .
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
[email protected]
Media Contact
David Rosen
Argot Partners
[email protected]
